Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.

RP03707 - Risen (Suzhou) Biosci

setidegrasib (ASP3082) - Astellas

HRS-4642 - Jiangsu Hengrui Pharma

Rasonque (daraxonrasib) - Revolution Medicines

LY3962673 - Eli Lilly

INCB161734 - Incyte

zoldonrasib (RMC-9805) - Revolution Medicines

MRTX1133 - BMS

http://www.ncbi.nlm.nih.gov/pubmed/42615854

Eunhye Jeon; Jaewon Song; Taebo Sim

Aug 20, 2026